Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

DLL3 protein, human × Endocrine × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 27 Magnetic Resonance Spectroscopy 21 pembrolizumab 17 Specimen Handling 16 Nivolumab 15 Everolimus 14 gallium Ga 68 dotatate 10 Ipilimumab 10 cabozantinib 9 trametinib 8 lenvatinib 8 dabrafenib 8 Cisplatin 8 Carboplatin 8 Temozolomide 7 Capecitabine 7 atezolizumab 6 X-Rays 5 Vemurafenib 5 Octreotide 5 Injections 5 Fluorodeoxyglucose F18 5 Etoposide 5 Disulfides 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 surufatinib 4 selpercatinib 4 amino-acid, glucose, and electrolyte solution 4 Surveys and Questionnaires 4 Paclitaxel 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06893783 2025-09-08

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡